Laxmi Dental record revenue, but no new margin target for FY27
Management walked back its 18-20% EBITDA margin guidance, citing a tougher domestic market. The stock must now price in lower profitability.
— 3 earlier stories on Laxmi Dental Ltd. →What's new
- Record Q4 revenue of ₹74 cr, driven by a rebound in the international lab business.
- US import tariffs fell from 50% to 10%, a key driver for the international segment.
- Management withdrew the prior FY27 guidance for 18-20% EBITDA margins.
Why this matters
A record top line paired with a guidance pullback is a classic signal of shifting profitability dynamics. Laxmi’s domestic aligner business faces stiffer competition, and management won’t promise the margins it did three months ago. That forces a reset in analyst models for FY27 earnings.
What we're watching
- Whether management offers a new, lower margin range in the coming quarters.
- Early traction for the iScope 360 subscription platform.
- The sustainability of international lab growth as tariff tailwinds normalize.
The full read
Laxmi Dental posted record quarterly revenue of ₹74 crore in Q4 FY26. The top line was lifted by a recovering international lab business after the US slashed import tariffs from 50% to 10%. The good news stops there. On the earnings call, management walked back its prior FY27 guidance for 18-20% EBITDA margins. The reason given was a mix of macro uncertainty and a tougher fight for share in the Indian aligner market. The company also launched iScope 360, an AI-connected platform for remote dental monitoring, but that is a longer-term story. The immediate takeaway is a guidance reset. Laxmi’s record quarter is real, but its promise of steady profit growth is now off the table.
Questions answered
- Why did management withdraw its FY27 margin guidance?
- Management cited rising macro-economic uncertainty and intensifying competition in the domestic aligner market. It would not reaffirm the prior 18-20% EBITDA margin target for FY27.
- What drove the record ₹74 crore quarterly revenue?
- The result was driven by a recovery in the international laboratory business. That recovery followed a sharp reduction in US import tariffs, which were cut from 50% to 10%.
- What is iScope 360?
- It is a new AI-connected remote dental platform. The company plans to use it for subscription-based monitoring services, creating a new digital revenue stream.
- How significant is the guidance change?
- It is a material shift. The company had previously guided for 18-20% EBITDA margins in FY27. The refusal to reaffirm that target signals management expects the domestic competitive environment to pressure profitability.
Laxmi Dental Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on LAXMIDENTL →- 30 May 2026 · 3:18 PM IST Laxmi Dental record revenue, but no new margin target for FY27
- 49d ago Laxmi Dental hits record revenue, then pulls FY27 guidance
- 50d ago Laxmi Dental re-announces audited Q4 and FY26 results it already filed.
- 50d ago Laxmi Dental posts 22% revenue growth, but a new labour-law charge hits profit